KRAS mutation: from undruggable to druggable in cancer
Lamei Huang(Sun Yat-sen University), Liwu Fu(Sun Yat-sen University)
Cited by 1,023
Related Papers
Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
|Cancer Research|2008|384
Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters
|Cancer Research|2010|348
Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer
|Molecular Cancer|2021|140
Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
|Journal for ImmunoTherapy of Cancer|2019|103